Matches in SemOpenAlex for { <https://semopenalex.org/work/W3031075823> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W3031075823 endingPage "4504" @default.
- W3031075823 startingPage "4504" @default.
- W3031075823 abstract "4504 Background: Clinical outcomes after curative treatment of resectable PDA remain suboptimal. To assess the potential of early control of systemic disease with multiagent peri-op CTx, we conducted a prospective trial in the National Clinical Trials Network. Methods: S1505 was a randomized phase II trial of peri-op CTx (12 weeks pre-, 12 weeks post-op) with either mFOLFIRINOX (Arm 1) or Gem/nabP (Arm 2). Eligibility required confirmed tissue diagnosis of PDA, ECOG PS 0 or 1, and resectable disease per Intergroup criteria. Primary outcome was 2-year overall survival (OS), using a “pick the winner” design; for 100 eligible patients (pts), accrual up to 150 pts was planned to account for cases deemed ineligible at central radiology review. We previously presented data on eligibility (ASCO 2019 abstr 4137). Here we present the final efficacy and toxicity results for the eligible pts. Results: From 2015 to 2018, 147 pts were enrolled; there were 102 eligible pts; 55 in Arm 1; 47 in Arm 2. For Arms 1 and 2 respectively: median age, 66 (44-76) and 64 (46-76) years; males, 36 (65%) and 24 (51%); and ECOG PS 0, 34 (62%) and 31 (66%) pts. Treatment details are shown in Table. For Arm 1 and Arm 2, respectively: Two-year OS was 41.6% and 48.8%; median OS was 22.4 months and 23.6 months. Neither arm’s 2-year OS estimate was statistically significantly higher than the a priori threshold of 40% (p=0.42 in Arm 1 and p=0.12 in Arm 2). Median disease-free survival (DFS) after resection was 10.9 months in Arm 1 and 14.2 months in Arm 2 (p=0.87). Conclusions: We have demonstrated: 1) two-year OS of 41.6% (median 22.4 months) with mFOLFIRINOX and 48.8% (median 23.6 months) with Gem/nabP for all eligible pts starting treatment for resectable PDA; 2) post-resection DFS of 10.9 months and 14.2 months, respectively; 3) adequate safety and high resectability rates with peri-op CTx; 4) little evidence that either regimen improves OS compared with the historical standard. Clinical trial information: NCT02562716 . [Table: see text]" @default.
- W3031075823 created "2020-06-05" @default.
- W3031075823 creator A5008330168 @default.
- W3031075823 creator A5014809735 @default.
- W3031075823 creator A5015750678 @default.
- W3031075823 creator A5015990700 @default.
- W3031075823 creator A5019995834 @default.
- W3031075823 creator A5033769736 @default.
- W3031075823 creator A5047818279 @default.
- W3031075823 creator A5048654505 @default.
- W3031075823 creator A5053703913 @default.
- W3031075823 creator A5065605420 @default.
- W3031075823 creator A5089839809 @default.
- W3031075823 creator A5091876744 @default.
- W3031075823 date "2020-05-20" @default.
- W3031075823 modified "2023-10-06" @default.
- W3031075823 title "SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA)." @default.
- W3031075823 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.4504" @default.
- W3031075823 hasPublicationYear "2020" @default.
- W3031075823 type Work @default.
- W3031075823 sameAs 3031075823 @default.
- W3031075823 citedByCount "67" @default.
- W3031075823 countsByYear W30310758232020 @default.
- W3031075823 countsByYear W30310758232021 @default.
- W3031075823 countsByYear W30310758232022 @default.
- W3031075823 countsByYear W30310758232023 @default.
- W3031075823 crossrefType "journal-article" @default.
- W3031075823 hasAuthorship W3031075823A5008330168 @default.
- W3031075823 hasAuthorship W3031075823A5014809735 @default.
- W3031075823 hasAuthorship W3031075823A5015750678 @default.
- W3031075823 hasAuthorship W3031075823A5015990700 @default.
- W3031075823 hasAuthorship W3031075823A5019995834 @default.
- W3031075823 hasAuthorship W3031075823A5033769736 @default.
- W3031075823 hasAuthorship W3031075823A5047818279 @default.
- W3031075823 hasAuthorship W3031075823A5048654505 @default.
- W3031075823 hasAuthorship W3031075823A5053703913 @default.
- W3031075823 hasAuthorship W3031075823A5065605420 @default.
- W3031075823 hasAuthorship W3031075823A5089839809 @default.
- W3031075823 hasAuthorship W3031075823A5091876744 @default.
- W3031075823 hasConcept C126322002 @default.
- W3031075823 hasConcept C141071460 @default.
- W3031075823 hasConcept C143998085 @default.
- W3031075823 hasConcept C146357865 @default.
- W3031075823 hasConcept C151730666 @default.
- W3031075823 hasConcept C2776694085 @default.
- W3031075823 hasConcept C2776907518 @default.
- W3031075823 hasConcept C2778336483 @default.
- W3031075823 hasConcept C2780258809 @default.
- W3031075823 hasConcept C31174226 @default.
- W3031075823 hasConcept C535046627 @default.
- W3031075823 hasConcept C71924100 @default.
- W3031075823 hasConcept C86803240 @default.
- W3031075823 hasConceptScore W3031075823C126322002 @default.
- W3031075823 hasConceptScore W3031075823C141071460 @default.
- W3031075823 hasConceptScore W3031075823C143998085 @default.
- W3031075823 hasConceptScore W3031075823C146357865 @default.
- W3031075823 hasConceptScore W3031075823C151730666 @default.
- W3031075823 hasConceptScore W3031075823C2776694085 @default.
- W3031075823 hasConceptScore W3031075823C2776907518 @default.
- W3031075823 hasConceptScore W3031075823C2778336483 @default.
- W3031075823 hasConceptScore W3031075823C2780258809 @default.
- W3031075823 hasConceptScore W3031075823C31174226 @default.
- W3031075823 hasConceptScore W3031075823C535046627 @default.
- W3031075823 hasConceptScore W3031075823C71924100 @default.
- W3031075823 hasConceptScore W3031075823C86803240 @default.
- W3031075823 hasFunder F4320332161 @default.
- W3031075823 hasIssue "15_suppl" @default.
- W3031075823 hasLocation W30310758231 @default.
- W3031075823 hasOpenAccess W3031075823 @default.
- W3031075823 hasPrimaryLocation W30310758231 @default.
- W3031075823 hasRelatedWork W1592992548 @default.
- W3031075823 hasRelatedWork W1990619355 @default.
- W3031075823 hasRelatedWork W2053144322 @default.
- W3031075823 hasRelatedWork W2080820783 @default.
- W3031075823 hasRelatedWork W2113566724 @default.
- W3031075823 hasRelatedWork W2283903823 @default.
- W3031075823 hasRelatedWork W2315587357 @default.
- W3031075823 hasRelatedWork W2621339296 @default.
- W3031075823 hasRelatedWork W2979112530 @default.
- W3031075823 hasRelatedWork W3032349186 @default.
- W3031075823 hasVolume "38" @default.
- W3031075823 isParatext "false" @default.
- W3031075823 isRetracted "false" @default.
- W3031075823 magId "3031075823" @default.
- W3031075823 workType "article" @default.